Results 151 to 160 of about 22,044 (247)

Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial

open access: yesArthritis &Rheumatology, Volume 77, Issue 6, Page 765-776, June 2025.
Objective Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks. Methods In this randomized, double‐blind, placebo‐controlled phase III trial, patients with treatment‐refractory IIM received SC abatacept (at 125 mg weekly)
Rohit Aggarwal   +5 more
wiley   +1 more source

Neutrophil extracellular traps in cancer: From mechanisms to treatments

open access: yesClinical and Translational Medicine, Volume 15, Issue 6, June 2025.
Neutrophil extracellular traps are intricately linked to the tumor microenvironment and play a crucial role in tumorigenesis, metastasis, and related complications. Consequently, NETs‐based tumor biomarkers and therapeutic strategies warrant significant attention.
Yifan Wang   +5 more
wiley   +1 more source

X-Ray Crystallographic Studies of the Fab and Fc Fragments of Human Myeloma Immunoglobulins

open access: yesCold Spring Harbor Symposia on Quantitative Biology, 1972
Richard L. Humphrey   +5 more
openaire   +3 more sources

An engineered PD1-Fc fusion produced in N. benthamiana plants efficiently blocks PD1/PDL1 interaction. [PDF]

open access: yesPlant Cell Rep
Izadi S   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy